We appreciate the interest in our article detailing the diagnosis and
classification of acute transverse myelitis (ATM) [1] and your comments.
Our primary goal was to delineate an approach to ATM, and therefore, we
did not describe the diagnosis and evaluation of patients with non-
inflammatory myelopathies. However, Dr. RomÜn raises an important point:
that we may mistakenly diagnose a patient who has nucleus pulposus
embolism (NPE) with ATM. We suggest that this is unlikely to occur for
several reasons. You and others have advanced our understanding of NPE,
[2-6, 7, 8] reporting that the majority of patients progress to nadir in
less than four hours. Additionally, most patients with NPE have
acellular, non-inflammatory CSF and no abnormal gadolinium enhancement on
spinal MRI imaging. [2-6] Indeed, the pathology in both humans and animals
with NPE [9-11] suggests ischemic infarction of the spinal cord rather
than a primary inflammatory process. Therefore, most patients with NPE
would be excluded by our criteria from a diagnosis of ATM.
We do not think that acute severe back pain is the exclusive domain
of NPE, and rather that this symptom may occur in patients with a variety
of spinal disorders, especially those with meningeal and radicular
involvement. Therefore, to add acute back pain as an exclusion criterion
for ATM would, in our opinion, be unfounded.
It is presently uncertain how common NPE is, though we agree that it
is likely under diagnosed. A patient with acute, non-inflammatory
myelopathy and disc space collapse at the site of deficit should be
considered to have NPE, especially if there is a recent
history of trauma. Even so, NPE likely represents a rare cause of
acute myelopathy, and it would be misleading to say that this entity is
“often” or “frequently” misdiagnosed.
Finally, there is no reported successful treatment of NPE, and
hyperbaric oxygen treatment should not be considered as “indicated”
treatment until studies suggest that it is effective.
References:
1.Transverse Myelitis Consortium Working Group. Proposed diagnostic
criteria and nosology of acute transverse myelitis. Neurology 2002;59:499-
505.
2.Toro G, RomÜn GC, Navarro-RomÜn L, Cantillo UJ, Serrano B, Vergara
I. Natural history of spinal cord infarction caused by nucleus pulposus
embolism. Spine 1994;19:360-366.
3.Bots GT, Wattendorff AR, Buruma OJ, Roos RA, Endtz LJ. Acute
myelopathy caused by fibrocartilaginous emboli. Neurology 1981;31:1250-
1256.
4.Case records of the Massachusetts General Hospital. Case 5-1991. N
Eng J Med 1991;324:322-332.
5.Davis GA, Klug GL. Acute-onset nontraumatic paraplegia in
childhood: Fibrocartilaginous embolism or acute myelitis? Child’s Nerv
Syst 2000;16:551-554.
6.Tosi L, Rigoli G, Beltramello A. Fibrocartilaginous embolism of the
spinal cord: A clinical and pathogenic reconsideration. J Neurol Neurosurg
Psychiatry 1996:60:55-60.
7. Schreck et al., Nucleus pulposus embolism. Spine, 1995; 22; 2463-
2466.
8. Yousef et al., Fibrocartilagenous embolism: an unusual cause of
spinal cord infarction. Am J Forensic Med Pathol, 1998; 4; 395-399.
9. Stedman et al., Intravascular cartilaginous emboli in the spinal
cord of turkeys. Avian Disease, 1998; 42; 423-428.
10. Cauzinille and Kornegay, Fibrocartilaginous embolism of the
spinal cord in dogs: review of 36 histologically confirmed cases and
retrospective study of 26 suspected cases. J. Vet Intern Med, 1996; 10;
241-245.
11. Junker et al., Fibrocartilaginous embolism of the spinal cord
(FCE) in juvenile Irish Wolfhounds. Vet Q, 2000; 22; 154-156